Smoldering, asymptomatic stage 1, and indolent myeloma
- Philip R. Greipp MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Of patients presenting with multiple myeloma, 5% to 15% satisfy criteria for the diagnosis of multiple myeloma but have no or minimal symptoms and do not require chemotherapy (NRC). These patients are classified as having smoldering, asymptomatic stage 1, or indolent multiple myeloma in order of their increasing risk of progression. We avoid chemotherapy, especially with alkylating agents in such patients, and we either closely monitor them or use a nonchemotherapeutic intervention. If significant bone lesions, renal failure, or hypercalcemia occur, chemotherapy or transplant is recommended. Patients with mild anemia or with small or isolated bone lesions who are asymptomatic or minimally symptomatic because of anemia may be monitored and are classified as having indolent multiple myeloma.
Unnecessary treatment with melphalan or cyclophosphamide probably has no benefit in multiple myeloma NRC and can cause significant risk. In long-term follow up, 25% of patients receiving alkylating agents develop myelodysplastic syndrome or acute leukemia. Patients who do not receive chemotherapy must be monitored closely to avoid complications of overt multiple myeloma, including anemia, bone lesions, renal failure, and hypercalcemia. We and others have begun to take a more active approach with the use of nonchemotherapeutic agents in selected patients. We use bisphosphonates in patients with bone lesions or osteoporosis or when there is a progressive rise in M-protein. We use dexamethasone alone in NRC multiple myeloma to reduce tumor burden in selected patients who do not yet have overt multiple myeloma or who are not candidates for chemotherapy. We use bisphosphonates to prevent osteoporosis in such patients. We use erythropoietin to correct anemia, and dexamethasone and erythropoietin together in patients with higher tumor burden (eg, indolent multiple myeloma).
Future progress in treating multiple myeloma NRC depends on better identification of new therapeutic targets that control progression from the stable asymptomatic to the progressive symptomatic phase of multiple myeloma. We need to better understand the biologic target of new agents like thalidomide to design more effective treatment for this early phase of multiple myeloma. Although these approaches may delay chemotherapy, it is not known whether survival is prolonged. Nonchemotherapeutic approaches must be systematically studied in clinical trials in order to be put to better use.
- Kyle RA, Greipp PR: Smoldering multiple myeloma. N Engl J Med 1980, 302:1347–1349. CrossRef
- Greipp PR, Kyle RA: Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983, 62:166–171.
- Boccadoro M, Gavarotti P, Fossati G, et al.: Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. B J Haematol 1984, 58:689–696.
- Witzig TE, Kyle RA, O’Fallon WM, et al.: Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994, 87:266–272. Fifty-seven patients with newly diagnosed smoldering multiple myeloma underwent a sensitive slide-based immunofluorescence procedure to detect circulating monoclonal plasma cells by their morphology and light chain immunoglobulin staining. Sixty-three percent of 16 patients with progression in 12 months had increased circulating plasma cells greater than 3 106/l. Only 10% of 41 patients who remained stable had increased circulating plasma cells.
- Hjorth M, Hellquist L, Holmberg E, et al.: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I—a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993, 50:95–102. This is a small but interesting study of 50 patients with asymptomatic stage 1 multiple myeloma who were randomized, 25 to melphalan prednisone and 25 to deferred therapy. The median time from diagnosis to start of therapy in the deferred group was 12 months. Eight patients began therapy because of an increasing M-protein. Nine patients developed symptomatic bone disease. Five patients developed anemia. Two patients with symptomatic bone disease required radiotherapy for vertebral fractures. Two patients in the melphalan prednisone group developed acute leukemia. No differences in response rate, response duration, or survival were observed between the two groups. The investigators concluded that the benefits of treatment deferral are to some extent outweighed by disease progression before the start of treatment. CrossRef
- Alexanian R. Localized and indolent myeloma. Blood 1980, 56:521–525.
- Rodjer S, Swolin B, Westin J: Monoclonal gammopathy —a diagnostic challenge. Illustrated by four cases of multiple myeloma with an unusually indolent (smoldering) course. Acta Med Scand 1983, 214:325–329. CrossRef
- Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group [see comments]. J Clin Oncol 1998, 16:593–602.
- Dhodapkar MV, Singh J, Mehta J, et al.: Anti-myeloma activity of pamidronate in vivo. Br J Haematol 1998, 103:530–532. Pamidronate therapy resulted in a significant reduction of marrow plasmacytosis and plasma cell labeling index (PCLI), together with durable (20 months) stabilization of immunoglobulin (Ig) levels and an increase in bone mineral density in the first patient, and a more than 50% reduction in Ig levels and bone marrow plasmacytosis in the second. CrossRef
- Garton JP, Gertz MA, Witzig TE, et al.: Epoetin alpha for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 1995, 155:2069–2074. CrossRef
- Singhal S, Mehta J, Desikan R, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571. Eighty-four patients with refractory myeloma received oral thalidomide as a single agent. Response was assessed based on a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least 6 weeks. The serum or urine levels of M-protein were reduced by at least 90% in 8 patients, at least 75% in 6 patients, at least 50% in 7 patients, and at least 25% in 6 patients, for a total rate of response (including minor responses) of 32%. Reductions in the M-protein levels occurred within 2 months in 78% of the patients with a response and were associated with a decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. CrossRef
- Zeldis JB, Williams BA, Thomas SD, et al.: S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Therap 1999, 21:319–330. CrossRef
- Cavo M, Baccarani M, Gobbi M, et al.: Prognostic value of bone marrow plasma cell infiltration in stage I multiple myeloma. Br J Haematol 1983, 55:683–690.
- Mariette X, Zagdanski AM, Guermazi A, et al.: Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999, 104:723–729. CrossRef
- Van de Berg BC, Lecouvet FE, Michaux L, et al.: Stage I multiple myeloma: value of MR imaging of the bone marrow in the determination of prognosis. Radiology 1996, 201:243–246.
- Smoldering, asymptomatic stage 1, and indolent myeloma
Current Treatment Options in Oncology
Volume 1, Issue 2 , pp 119-126
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Division of Hematology, Department of Internal Medicine, Mayo Clinic and Foundation, 200 Southwest 1st Avenue, 55905, Rochester, MN, USA